Age-Related Variation in the Provision of Primary Care Services and Medication Prescriptions for Patients with Cardiovascular Disease

Qiang Tu 1,*, Karice Hyun 1,2, Nashid Hafiz 1, Andrew Knight 3,4, Charlotte Hespe 5, Clara K. Chow 6,7, Tom Briffa 8, Robyn Gallagher 9, Christopher M. Reid 10,11, David L. Hare 12,13, Nicholas Zwar 4,14, Mark Woodward 15,16, Stephen Jan 15, Emily R. Atkins 7,15, Tracey-Lea Laba 17, Elizabeth Halcomb 18, Tim Usherwood 7,15, Laurent Billot 15 and Julie Redfern 1,15

1 Faculty of Medicine and Health, School of Health Sciences, The University of Sydney, Sydney 2050, Australia
2 Department of Cardiology, Concord Hospital, Sydney 2139, Australia
3 The Primary and Integrated Care Unit, South Western Sydney Local Health District, Sydney 2170, Australia
4 School of Population Health, University of New South Wales, Sydney 2052, Australia
5 School of Medicine, The University of Notre Dame, Sydney 2010, Australia
6 Research Education Network, Western Sydney Local Health District, Sydney 2151, Australia
7 Westmead Applied Research Centre, Faculty of Medicine and Health, The University of Sydney, Westmead 2154, Australia
8 School of Population and Global Health, The University of Western Australia, Perth 6009, Australia
9 Faculty of Medicine and Health, Sydney Nursing School, University of Sydney, Sydney 2006, Australia
10 School of Population Health, Curtin University, Perth 6102, Australia
11 School of Public Health and Preventive Medicine, Monash University, Melbourne 3004, Australia
12 Faculty of Medicine, Dentistry and Health Sciences, University of Melbourne, Melbourne 3010, Australia
13 Department of Cardiology, Austin Health, Heidelberg 3084, Australia
14 Faculty of Health Sciences & Medicine, Bond University, Gold Coast 4226, Australia
15 The George Institute for Global Health, Imperial College London, London NW9 7PA, UK
16 The George Institute for Global Health, School of Public Health, Imperial College London, London NW9 7PA, UK
17 Pharmacy Program, Clinical and Health Sciences Unit, University of South Australia, Adelaide 5001, Australia
18 School of Nursing, University of Wollongong, Wollongong 2522, Australia

* Correspondence: qiang.tu@sydney.edu.au; Tel.: +61-481-131-656

Abstract: As population aging progresses, demands of patients with cardiovascular diseases (CVD) on the primary care services is inevitably increased. However, the utilisation of primary care services across varying age groups is unknown. The study aims to explore age-related variations in provision of chronic disease management plans, mental health care, guideline-indicated cardiovascular medications and influenza vaccination among patients with CVD over differing ages presenting to primary care. Data for patients with CVD were extracted from 50 Australian general practices. Logistic regression, accounting for covariates and clustering effects by practices, was used for statistical analysis. Of the 14,602 patients with CVD (mean age, 72.5 years), patients aged 65–74, 75–84 and ≥85 years were significantly more likely to have a GP management plan prepared (adjusted odds ratio (aOR): 1.63, 2.09, 1.93, respectively, p < 0.05) and have a formal team care arrangement (aOR: 1.49, 1.8, 1.65, respectively, p < 0.05) than those < 65 years. Patients aged ≥65 years were more likely to be prescribed blood-pressure-lowering medications and to be vaccinated for influenza. However, the adjusted odds of being prescribed lipid-lowering and antiplatelet medications and receiving mental health care were significantly lowest among patients ≥85 years. There are age-related variations in provision of primary care services and pharmacological therapy. GPs are targeting care plans to older people who are more likely to have long-term conditions and complex needs.

Keywords: cardiovascular disease; age; secondary prevention; primary care; risk factors
1. Introduction

Cardiovascular disease (CVD), including coronary heart disease, myocardial infarction, hypertension, heart failure, stroke, peripheral vascular disease, carotid stenosis and renal artery stenosis, is the leading cause of morbidity and mortality globally, which dominates healthcare and challenges health systems [1]. The world’s population aged 60 years and over is projected to increase from 1 billion in 2020 to 2.1 billion by 2050 [2]. There are a number of underlying risk factors for developing CVD, which include non-modifiable (age, ethnicity, gender, genetics) and modifiable risk factors (elevated blood pressure, diabetes, smoking, overweight, physical inactivity, excessive alcohol consumption and underuse of prescription medications) [3]. To achieve the optimal management of CVD risk and reduce the burden of established CVD, the European Society of Cardiology guideline advocates implementing secondary prevention of CVD in primary care [4]. It is widely recognised by the World Health Organisation and reflected in international guidelines that effective secondary prevention strategies for CVD include vigorous management, monitoring and treatment to target of risk factors, appropriate treatments with multiple evidence-based cardiovascular medications and timely receipt of chronic care services in primary care [5,6].

Australia has a universal health care insurance system (Medicare), which is the primary funding mechanism for subsidising primary care services and pharmaceuticals for Australian citizens and residents [7]. Under Medicare, the Australian health system aims to achieve its core objectives enabling patients to have access to appropriate primary care services and medications [8,9]. Medicare comprises two elements: the Medical Benefits Schedule (MBS) and the Pharmaceutical Benefits Scheme (PBS). The MBS includes Chronic Disease Management Plan (CDMP) items and GP Mental Health Care items. CDMP items provide rebates for (i) general practice management plans (GPMPs) to foster systematic care planning, (ii) team care arrangements (TCAs) to improve multidisciplinary-based integrated care, and (iii) reviews of both GPMP and TCA to support continuity of care [10]. As part of MBS-subsidised items, GP mental health care items provide rebates for (i) assessment and preparation of a mental health management plan, (ii) review of the management plan, and (iii) mental health treatment consultations [11]. Under the PBS, the government subsidises the cost of evidence-based cardiovascular medications including blood pressure-lowering, lipid-lowering, and antiplatelet medications [12,13]. Evidence has demonstrated that the utilisation of MBS- and PBS-subsidised health services and medications are associated with a substantial reduction in cardiovascular hospitalisation and premature mortality [14].

Despite widespread efforts made in the secondary prevention of CVD in primary care through universal health coverage, gender and ethnicity-related variations persist. Areas of variability include utilisation of primary care services such as chronic disease management, mental health care, cardiovascular medications, and influenza vaccination [15–17]. As population aging progresses, demands on the existing primary care services will be inevitably increased and require more knowledge about the utilisation of primary care services across varying age groups [18]. Studies have suggested that age is one of the key determinants that influence health-seeking behaviour in primary care [19,20]. However, there have been limited studies that have examined whether usage of primary care services and prescribed medications vary by age [21–25]. Most previous studies in assessing age-related differences in health services use treated patients aged 65 years and above as a single homogeneous group [21], lack focus on a specific disease condition (e.g., CVD) [23,24], or do not consider secondary prevention at the primary care level [22,25]. Therefore, the aim of this study was to evaluate age-related variation in the utilisation of primary care services including CDMPs, mental health care, prescription of guideline-indicated medications and influenza vaccination among patients with CVD presenting to primary care.

2. Materials and Methods

A retrospective cross-sectional study was conducted using data from the QUEL study an Australia–based cluster randomised controlled trial that recruited 50 primary care practices across four states, including New South Wales, Victoria, South Australia and
Queensland [26]. Ethics approval has been obtained from the New South Wales Cancer Institute Population and Health Services Research Ethics Committee (no. HREC/18/CIPHS/44). Waiver of participant consent has been granted for this baseline data analysis due to the characteristics of extraction of de-identified data from electronic health record system. Given it is a practice-level study, participating general practices have consented to provide de-identified data for analysis.

2.1. Practices and Participants

Primary care practices were eligible if they (i) were located in Australia, (ii) managed ≥ 100 patients with CVD annually, and (iii) installed compatible data extraction software. Inclusion criteria for patients (i) were aged ≥ 18 years, (ii) a documented diagnosis of CVD as recorded by the general practitioner including coronary heart disease, acute coronary syndrome, myocardial infarction, heart failure, stroke, and peripheral vascular disease, and (iii) had visited the participating practice ≥ 3 times in the previous 24 months. Inclusion of patients was based on data entered into electronic medical records by treating primary care providers at each practice and hence diagnosis was a clinical record and not verified by source documentation.

2.2. Data Collection

Data extraction was conducted by an external population health analytics and reporting platform named Pen Computer Systems (Pen CS) [27]. De-identified data between 2018 and 2019 were automatically extracted from 50 participating primary care practices. Extracted data were stored on the university computer server under password protection. To ensure privacy, the practice name was replaced by a specific practice number during data extraction and a statistician who was blinded to the practice number performed data pooling and analysis. A range of demographic and clinical data were extracted including age, gender, indigenous status, CVD risk factors (blood pressure, total cholesterol, high-density lipoproteins, low-density lipoproteins, glycated haemoglobin (HbA1c), smoking status, alcohol consumption, body mass index (BMI)), mental health diagnoses, prescribed medications, MBS items and influenza vaccination. Three types of guideline-indicated cardiovascular medications prescribed between 2018 and 2019 were also extracted. This included blood pressure-lowering (beta-blockers, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, calcium channel blockers and diuretics), lipid-lowering, and antiplatelet medications. In addition, claimed MBS items were extracted to enable age-related comparison in the receipt of both CDMPs and mental health care. Specific descriptions for MBS items are presented in Table 1. The extracted data were securely uploaded to the university’s research data storage platform for analysis.

| Australia Universal Insurance System Elements | Item Name and Number | Rebate Amount (AUD) | Description |
|-----------------------------------------------|----------------------|--------------------|-------------|
| Medicare Medical Benefits Schedule (MBS)      | 721 Preparation of a General Practice Management Plan (GPMP) | $148.75 | Rebate for GP to prepare a management plan for patients with a chronic or terminal medical condition |
| Chronic Disease Management Plan (CDMP) Items  | 723 Coordination of Team Care Arrangements (TCAs) | $117.90 | Rebate for GP to develop management plan for patients with a chronic or terminal medical condition and complex needs requiring ongoing care from a multidisciplinary team (at least three care providers) |
|                                               | 732 Review of a GPMP and/or TCA | $74.30 | Rebate for GP to review a GPMP and/or TCA |

Table 1. Medicare Benefits Schedule for chronic disease management and mental health care in general practice and Pharmaceutica Benefits Scheme.
2.3. Outcomes

The primary outcome of interest was the uptake of CDMP by patients with CVD (Table 1). Secondary outcomes included (1) mental health claims among patients with CVD who were documented as having a mental health disorder, (2) medication prescription (blood pressure-lowering, lipid-lowering, and antiplatelet medications) written by GPs among patients with CVD, and (3) influenza vaccination. Specific descriptions for each MBS item are detailed in Table 1 [28].

2.4. Statistical Analysis

Patients were stratified into four age groups: adults < 65 years, youngest-old (65–74 years), middle-old (75–84 years), and oldest-old (≥ 85 years). Categorical variables were summarised as number and percentage and continuous variables were summarised as mean and standard deviation (SD) after visually checking that the distribution is normal. Cochran-Armitage trend test and univariable linear regression were used to test for the univariable trend of binary and continuous patient characteristics and outcomes, respectively, across the increasing age groups. For adjusted analyses, multivariable logistic regression models were performed using generalised estimating equations to account for the clustering effect of practices. We included the following independent variables in the models: age (65–74, 75–84, ≥ 85 vs. <65 years), gender (male vs. female), Indigenous status (yes vs. no), current smoker (yes vs. no), alcohol drinker (yes vs. no), type 2 diabetes (yes vs. no), BMI, systolic blood pressure, and total cholesterol. Based on the clinical significance, risk factors for CVD were included in the models as covariates to adjust for the severity of cardiovascular risk in patients. The adjusted odds ratio (aOR) and 95% confidence intervals (95% CIs) were estimated to present the aged-related variations. When analysing the receipt of mental health items, only patients with CVD who were documented as having a mental health disorder were included. A two-sided p-value of < 0.05 was considered statistically significant. All statistical analyses were undertaken using SAS version 9.4.

3. Results

3.1. Patient Characteristics

A total of 14,602 patients with CVD were included in the study. Demographic and clinical characteristics of patients, stratified by age, are presented in Table 2. There were 8842 (61%) male patients. The mean age was 72.5 (SD 12.7) years: 3666 (25%) patients were
aged < 65 years, 4229 (29%) patients were aged 65–74 years, 4108 (28%) patients were aged 75–84 years and 2599 (18%) patients were aged ≥ 85 years. In total, 3078 (21%) patients with CVD had coexisting type 2 diabetes. Compared with those < 65 years, patients with CVD in all age categories ≥ 65 years (65–74, 75–84 and ≥ 85 years) were significantly less likely to be a current smoker (13%, 6%, 2%, respectively, vs. 22%, \( p < 0.0001 \)), alcohol drinker (60%, 55%, 48%, respectively, vs. 63%, \( p < 0.0001 \)) or have type 2 diabetes (22%, 24%, 19%, respectively, vs. 17%, \( p < 0.0001 \)).

Table 2. Demographic and clinical characteristics of the cohort with established CVD by age.

| Variable | <65 (n = 3666) | 65–74 (n = 4229) | 75–84 (n = 4108) | ≥85 (n = 2599) | Total (n = 14602) | Data Available n (%) | \( p \)-Value |
|----------|----------------|-----------------|-----------------|--------------|------------------|----------------------|-------------|
| Male, n (%) | 2453 (67) | 2766 (65) | 2477 (60) | 1146 (44) | 8842 (61) | 14,601 (99) | <0.0001 |
| Age, mean (SD) (years) | 55.6 (7.61) | 69.9 (2.83) | 79.3 (2.88) | 89.8 (4.04) | 72.5 (12.72) | 14,602 (100) | <0.0001 |
| Indigenous, N (%) | 169 (5) | 101 (3) | 55 (2) | 15 (1) | 340 (3) | 12,418 (85) | <0.0001 |
| Diagnosis of diabetes, n (%) | 65 (2) | 63 (1) | 22 (1) | 13 (1) | 163 (1) | 14,602 (100) | <0.0001 |
| Systolic blood pressure (mm Hg), mean | 129.5 (16.82) | 132.4 (17.13) | 133.0 (18.25) | 133.6 (20.02) | 132.1 (17.97) | 13,968 (96) | <0.0001 |
| Diastolic blood pressure (mm Hg), mean | 79.7 (29.02) | 75.1 (23.50) | 72.3 (30.20) | 71.6 (42.11) | 74.9 (30.78) | 13,976 (96) | <0.0001 |
| Total cholesterol (mmol), mean | 4.5 (1.22) | 4.2 (1.09) | 4.1 (1.07) | 4.3 (1.15) | 4.2 (1.14) | 13,309 (91) | <0.0001 |
| High-density lipoprotein (mmol/L), mean | 1.3 (0.37) | 1.3 (0.39) | 1.3 (0.41) | 1.4 (0.40) | 1.3 (0.39) | 12,761 (87) | <0.0001 |
| Low-density lipoprotein (mmol/L), mean | 2.4 (1.03) | 2.2 (0.93) | 2.1 (0.88) | 2.2 (0.95) | 2.2 (0.95) | 12,634 (87) | <0.0001 |
| Body mass index, mean (SD) | 31.1 (11.63) | 30.3 (11.36) | 28.8 (7.93) | 26.8 (10.04) | 29.5 (10.41) | 11,633 (80) | <0.0001 |
| Current smoker, N (%) | 2088 (75) | 2616 (77) | 2471 (73) | 1179 (41) | 6114 (44) | 13,968 (96) | <0.0001 |
| Alcohol drinker, N (%) | 753 (22) | 494 (13) | 220 (6) | 49 (2) | 1516 (11) | 13,250 (91) | <0.0001 |
| HbA1c for those with diabetes, mean (SD) | 7.0 (5.24) | 7.8 (7.66) | 7.6 (7.10) | 8.1 (8.84) | 7.6 (7.23) | 8337 (57) | <0.0001 |
| Achieved cardiovascular risk factor targets | | | | | | | |
| Systolic blood pressure < 130 mm Hg | 1763 (50) | 1708 (42) | 1651 (42) | 992 (41) | 6114 (44) | 13,968 (96) | <0.0001 |
| Diastolic blood pressure < 80 mm Hg | 1775 (51) | 2637 (65) | 2919 (74) | 1840 (76) | 9207 (66) | 13,976 (96) | <0.0001 |
| High-density lipoprotein > 1.0 mmol/L | 2163 (70) | 2831 (74) | 2805 (75) | 1698 (81) | 9497 (74) | 12,761 (87) | <0.0001 |
| Low-density lipoprotein < 1.8 mmol/L | 892 (29) | 1452 (38) | 1524 (41) | 747 (36) | 4615 (37) | 12,634 (87) | <0.0001 |
| Total cholesterol < 4.0 mmol/L | 1267 (39) | 1920 (49) | 1964 (51) | 1067 (46) | 6218 (47) | 13,309 (91) | <0.0001 |
| HbA1c ≤ 7% | 1440 (75) | 1913 (76) | 1980 (79) | 1106 (81) | 6349 (77) | 8337 (57) | <0.0001 |

Mean systolic and diastolic blood pressure of the total cohort were 132.1 mmHg and 74.9 mmHg, respectively. Statistically significant differences in the systolic and diastolic blood pressure were found among the four age groups where age-related increase in systolic blood pressure and decrease in diastolic blood pressure were noted. Patients with CVD aged < 65 years had the highest prevalence of mental health disorder compared with other three age groups.

3.2. Provision of Chronic Disease Management Plans

Of the total cohort, the proportion of patients with CVD who received ‘preparation of GPMP’, ‘coordination of TCA’ and ‘review of GPMP or TCA’ were 44%, 38% and 35%, respectively (Table 3). In particular, for the patient group < 65 years, the proportion of receiving GPMP, TCA and review was only 35%, 30% and 26%, respectively. The proportion of patients < 65 years who had both GPMP and review was lower, being only at 22%.
Table 3. Receipt of primary care services in the cohort with established CVD by age.

| Age Group | Components of Chronic Disease Management Plans | Coordination of TCA | Review of GPMP or TCA | Preparation of GPMP or TCA & Review of GPMP or TCA | Mental health care items | Guideline recommended prescribed cardiovascular medication | Blood pressure-lowering medication | Lipid-lowering medication | Antiplatelet medication | Combination of blood pressure-lowering medication, lipid-lowering medication and antiplatelet medication | Flu vaccination |
|-----------|-----------------------------------------------|---------------------|-----------------------|-------------------------------------------------|------------------------|---------------------------------------------------------------|-------------------------------|-----------------------------|------------------------|----------------------------------------------------------------------------------------------|------------------|
| <65 (<n = 3666)> | 1296 (35) | 1093 (30) | 963 (26) | 797 (22) | 231 (22) | 94 (9) | 153 (15) | 2162 (59) | 2155 (59) | 1772 (48) | 1113 (30) | 1982 (54) |
| 65–74 (<n = 4229)> | 1939 (46) | 1659 (39) | 1503 (36) | 1245 (29) | 145 (14) | 52 (5) | 116 (11) | 3001 (71) | 2685 (63) | 2178 (52) | 1494 (35) | 3317 (78) |
| 75–84 (<n = 4108)> | 2101 (51) | 1808 (44) | 1709 (42) | 1425 (35) | 71 (8) | 29 (3) | 98 (11) | 3034 (74) | 2540 (62) | 1985 (48) | 1333 (32) | 3532 (86) |
| ≥85 (<n = 2599)> | 1046 (40) | 938 (36) | 901 (35) | 726 (28) | 19 (3) | 5 (1) | 31 (5) | 1783 (69) | 1137 (44) | 1069 (41) | 545 (21) | 2190 (84) |
| Total (<n = 14602>) | 6382 (44) | 5498 (38) | 5076 (35) | 4193 (29) | 466 (13) | 180 (5) | 398 (11) | 9980 (68) | 8517 (58) | 7004 (48) | 4485 (31) | 11,021 (76) |

*p*-Value

-0.0001
-0.0001
-0.0001
-0.0001
-0.0001
-0.0001
-0.0001
-0.0001
-0.0001
-0.0001
-0.0001
-0.0001
-0.0001

Significant age-related differences in the receipt of all three sub-types of CDMPs were found such that an inverted U-shaped relationship with age in utilisation of GPMP, TCA and review occurred. The utilisation rate of GPMP, TCA and review was lower in the extreme age groups (<65 and ≥85 years) than in the middle two age groups (65–84 years). After adjusting for demographic and clinical factors, the difference in the proportion among the age groups receiving these three sub-types of CDMPs remained significant (Table 4). Patients with CVD aged 65–74, 75–84 and ≥85 years were significantly more likely to have a GPMP prepared (aOR: 1.6, 1.88 and 1.55, respectively, \( p < 0.05 \)), have a TCA (aOR: 1.49, 1.8, 1.65, respectively, \( p < 0.05 \)) and have a review of GPMP or TCA (aOR: 1.63, 2.09, 1.93, respectively, \( p < 0.05 \)) than those <65 years.

Table 4. Multiple-adjusted Odds Ratios by age group (reference group <65 years) for the receipt of MBS items and guideline-recommended prescription medications and achievement of control targets in the cohort with established CVD.

| Outcomes | Age (years) | Odds Ratio (95% Confidence Interval) | p-Value |
|----------|-------------|--------------------------------------|---------|
| Components of Chronic Disease Management Plans | 65–74 | 1.6 (1.33, 1.91) | 0.0026 |
| | 75–84 | 1.88 (1.49, 2.36) | |
| | ≥85 | 1.55 (1.11, 2.16) | |
| | 65–74 | 1.49 (1.27, 1.75) | |
| Coordination of TCA | 75–84 | 1.8 (1.43, 2.25) | 0.0029 |
| | ≥85 | 1.65 (1.17, 2.33) | |
| | 65–74 | 1.63 (1.43, 1.86) | |
| Review of GPMP or TCA | 75–84 | 2.09 (1.64, 2.66) | 0.0014 |
| | ≥85 | 1.93 (1.39, 2.7) | |
Table 4. Cont.

| Outcomes                                      | Age (years) | Odds Ratio (95% Confidence Interval) | p-Value |
|-----------------------------------------------|-------------|--------------------------------------|---------|
| Mental health care items                      |             |                                      |         |
| Preparation of a GP Mental Health Treatment Plan * | 65–74       | 0.55 (0.38, 0.82)                    | 0.0005  |
|                                               | 75–84       | 0.3 (0.21, 0.45)                     |         |
|                                               | ≥85         | 0.17 (0.11, 0.27)                    |         |
|                                               | 65–74       | 0.51 (0.36, 0.74)                    | 0.0010  |
| Review of a GP Mental Health Treatment Plan * | 75–84       | 0.34 (0.19, 0.61)                    |         |
|                                               | ≥85         | 0.11 (0.05, 0.23)                    |         |
|                                               | 65–74       | 0.69 (0.49, 0.96)                    |         |
| GP Mental Health Treatment Consultation *     | 75–84       | 0.69 (0.49, 0.99)                    | 0.0481  |
|                                               | ≥85         | 0.49 (0.31, 0.76)                    |         |
| Guideline recommended prescribed cardiovascular medication |          |                                      |         |
| Blood pressure-lowering medication            | 65–74       | 1.58 (1.33, 1.88)                    | 0.0024  |
|                                               | 75–84       | 1.92 (1.55, 2.37)                    |         |
|                                               | ≥85         | 1.8 (1.34, 2.42)                     |         |
| Lipid-lowering medication                    | 65–74       | 1.06 (0.94, 1.18)                    | 0.0141  |
|                                               | 75–84       | 0.92 (0.83, 1.02)                    |         |
|                                               | ≥85         | 0.54 (0.44, 0.67)                    |         |
| Antiplatelet medication                       | 65–74       | 1.02 (0.88, 1.17)                    | 0.0421  |
|                                               | 75–84       | 0.87 (0.74, 1.03)                    |         |
|                                               | ≥85         | 0.74 (0.58, 0.93)                    |         |
| Combination of blood pressure-lowering medication, lipid-lowering medication and antiplatelet medication | 65–74 | 1.12 (0.93, 1.35) | 0.0183 |
|                                               | 75–84       | 0.93 (0.71, 1.22)                    |         |
|                                               | ≥85         | 0.64 (0.44, 0.94)                    |         |
| Flu vaccination                               | 65–74       | 3.13 (2.6, 3.77)                     | <0.0001 |
|                                               | 75–84       | 6.19 (5.19, 7.39)                    |         |
|                                               | ≥85         | 8.23 (6.45, 10.49)                   |         |

Adjusted for age groups, gender, Indigenous status, current smoker, type 2 diabetes, systolic blood pressure, total cholesterol, body mass index categories and alcohol consumption. * Denominator: those who was documented as having mental health disorder.

3.3. Provision of Mental Health Care

In total, 25% of patients with CVD were documented as having a mental health disorder. Patients aged < 65 years (28%) were significantly more likely to be documented as having a mental health disorder compared with those aged 65–74 (25%), 75–84 (22%), and ≥ 85 years (24%) (p < 0.0001). Increasing age was associated with a lower proportion receiving a GP mental health treatment plan, review of said plan, and documentation regarding mental health treatment consultation. The adjusted odds of receiving mental health treatment consultation (0.69, 0.69 and 0.49, respectively, p < 0.05), preparation of GP mental health care plan (0.55, 0.3 and 0.17, respectively, p < 0.05), and review of a GP mental health treatment plan (0.51, 0.34 and 0.11, respectively, p < 0.05) was significantly lower amongst patients aged 65–74, 75–84 and ≥85 years in comparison with those aged < 65 years (Table 4). Patients ≥ 85 years who were provided ‘preparation of a GP Mental Health Treatment Plan’, ‘Review of a GP Mental Treatment Plan’, and ‘Mental health Treatment Consultation’ were only 3%, 1% and 5%, respectively.

3.4. Prescription of the Guideline-Recommended Cardiovascular Medications

The proportion of patients prescribed evidence-based medications was lower in the oldest and youngest age groups (aged < 65 and aged ≥ 85 years) than in the middle age groups (65–84 years old) (Table 3). Patients aged ≥ 85 years had fewer prescriptions of combination cardiovascular medication than the younger age groups. Patients aged 75–84 years had the highest proportion (74%) of guideline-indicated blood pressure-lowering medication prescriptions while patients aged < 65 years had the lowest (59%). Patients aged 65–74 years were prescribed more (63% and 52%, respectively) lipid-lowering and antiplatelet medications than the other three groups, while patients aged ≥ 85 years had the lowest prescription of lipid-lowering and antiplatelet medications (44% and 41%). After adjustment for clinical and demographic factors, the age differences in the prescrip-
tion of these three types of medications remained significantly different. Patients aged 75–84 years had 1.9 times the odds of receiving blood pressure-lowering medication than those aged < 65 years. Patients aged 65–74 had a more than 96% and 38% higher likelihood of being prescribed lipid-lowering medication and antiplatelet than those aged ≥ 85 years, respectively. Further, prescription of lipid–lowering medications and antiplatelet medications across all four age groups were consistently less frequent than the prescription of blood pressure–lowering medications.

3.5. Influenza Vaccination

Seventy-five percent of the cohort were vaccinated against influenza. Patients aged 75–84 years had the highest proportion of receiving influenza vaccination while those aged < 65 years had the least. The adjusted odds of receiving influenza vaccination were significantly higher amongst patients aged 65–74, 75–84 and ≥85 years (aOR; 3.13, 6.19 and 8.23, respectively, \( p < 0.05 \)) compared with those aged < 65 years.

4. Discussion

To the best of our knowledge, this is the first study to comprehensively evaluate age-related variations in the provision of primary care services and guideline-indicated prescribed medications among patients with CVD. Overall, we found substantial age-related variation in the provision of CDMPs, mental health care, guideline-indicated prescribed medications, and influenza vaccination, even after adjusting for social-demographic and clinical factors.

Age-related variation in provision of Medicare-funded CDMP items was found in patients with CVD who attended primary care practices. Our study found that CDMP items were not commonly claimed by GPs treating patients with CVD, although absence of claiming does not necessarily reflect that chronic disease support is not occurring. It revealed an overall underutilisation of CDMP for patients with CVD, particularly for the younger cohort who might benefit the most from these item numbers due to the associated subsidised access to allied health services. Previous studies have shown that increased use of GPMP was associated with reduced hospitalisation in older patients with chronic conditions \[14,29\]. Therefore, our results are noteworthy and deserve further investigation as to why these items were not commonly used or claimed. Understanding the causes of variation is important to develop targeted quality improvement programs. Our findings in CDMP items generally support an increasing utilisation of GPMP, TCA and a review with advancing age before 85 years. Given that older people were more prone to more chronic conditions and multimorbidity than their younger counterparts, it is difficult to infer whether increased use of CDMPs equate to better care for CVD. However, increased CDMP use may imply a positive finding suggesting that the GPs are appropriately targeting care plans and providing chronic disease management where they think it is likely to have most benefit for patients. The increased use of CDMP items observed may also reflect the patients’ desire to access allied health funding for competing chronic conditions and thus represents an appropriate response to greater needs for chronic care along with increasing age. However, the utilisation rate of CDMP items declined moderately in the age group of ≥ 85 years, generating an overall inverted U–shaped relationship with age. This trend may be explained by the life expectancy theory. In Australia, the average life expectancy was 82.8 years \[30\]. As health care utilisation often peaks at the end of life, it partly explained our finding that the highest proportion of using chronic disease management plans occurred in the 75–84 age group and subsequently a moderate decrease in the ≥85 age group \[31\]. The relatively lower percentage of generating CDMPs in the ≥85 age group may be associated with time and resource constraints, substitution of institutional care, functional decline or frailty of older people impeding their ability to seek healthcare, patient preference near the end of life \[24\]. Overall, there is a potential opportunity to increase the quality of healthcare in patients with CVD by better utilisation of proactive healthcare planning and reviews.
With respect to provision of mental health care, our results showed an age-related variation. The present study found that, among patients with comorbid CVD and mental health disorders, preparation of GP mental health treatment plans, review of a GP mental health treatment plan and mental health treatment consultation steadily decreased with increasing age, from 22%, 9%, 15% in age group of <65 years to 13%, 5%, 1% in age group of ≥85 years. Our results differ from previous research that found the elderly had more positive healthcare-seeking attitudes regarding mental health concerns than younger patients [20]. Potential reasons explaining the age-related shift in mental health service use in our study may include prioritisation of physical health care above mental health care for older people, the acknowledgment of mental health disorders as a normal or inevitable part of aging process, perceived stigma, or discrimination for seeking mental health treatment, or poor mental health literacy of older patients [32,33]. Qualitative review of these findings would assist in addressing the gap in care and therefore improving both health outcomes and quality of life. Mental health disorders, such as depression, can lead to poor health behaviours including unhealthy diet, smoking, physical inactivity, and medication nonadherence [34]. Poor health behaviours act as barriers against secondary prevention of CVD and contribute to adverse CVD outcomes [21]. Therefore, our results indicate it is necessary to continue to optimise mental health care among patients with CVD in primary care settings through identification, assessment and treatment of mental health issues and integration of mental health into chronic disease treatment.

Our results also revealed the existence of significant variation across age-groups in the prescription of guideline-directed CVD medications in Australia. This finding is consistent with a previous Scottish population-based cross-sectional study, which found that people aged 65–84 years were prescribed more evidence-based CVD medications than those ≥ 85 years [35]. The finding that relatively less prescription of lipid-lowering medication and antiplatelet medication among patients aged ≥ 85 years than those aged 65–84 years observed in our study is also consistent with previous studies. An Australian study showed that only 3% of centenarians received lipid-lowering medications compared to 49% of those aged 65 to 74 [23]. Another study from the Netherlands found that a continuous increase in the use of lipid-lowering medications in patients with CVD up to the age of 85 years after which its use markedly declined [12]. In addition, a retrospective cohort study in the USA has found that patients older than 75 years with myocardial infarction were less likely to be prescribed aspirin than those aged 65 to 74 years [36]. The current study also showed that among older patients aged > 65 years, combination of blood pressure-lowering medication, lipid-lowering medication and antiplatelet medication gradually declined with increasing age. It is difficult to interpret whether the decreased prescription at older ages reflects clinical judgement, limitations of PBS, patient-centred clinical decision making, suitability of CDMP or patient preference. It may be partly attributed to a treatment-risk paradox, whereby GP’s concerns on comorbidities, age-related side effects and intolerance of medications, contraindications for pharmacological therapy of oldest-old population due to their changing physiological characteristics [12,21,37,38]. Therefore, based on safety considerations, GPs and patients may tend toward conservative treatment aligned with a philosophy of “de-prescribing”. Further, our study found that prescription of lipid-lowering (44%) and antiplatelet medications (41%) were much lower than blood pressure-lowering medications (69%) among patients aged ≥ 85 years. However, the gap was smaller among the other three age groups. Similar results were shown in a previous study that the use of blood pressure-lowering medications among patients ≥ 75 with coronary heart disease was more than three times higher than lipid-lowering medications [12]. These findings further highlight the GP’s demand of stronger worded CVD guidelines for prescribing preventive care in the older years and importance of age-specific consideration in prescribing CVD medications by GPs, particularly for older people who have competing medical needs and are the users of polypharmacy.

It was not surprising to see the proportion receiving influenza vaccination increased with age, given people aged ≥ 65 years are eligible for free influenza vaccination in
Australia, whereas those aged < 65 years need a specific indication. This positive finding was aligned with the recommendation of national immunisation program. A systematic review and meta-analysis has found that influenza vaccination was associated with a lower risk of cardiovascular mortality and adverse cardiovascular events [39]. Therefore, secondary CVD care needs to be funded for influenza vaccination under the age of 65 and policy makers should consider adding them to the priority group. Consideration should also be given to including secondary prevention of CVD as an indication in the subsidised influenza vaccination scheme.

The reasons behind the observed variations may be complex. It is important to raise awareness among health providers that optimal management of patients with CVD with careful age consideration is crucial to improve outcomes. Understanding these variations more thoroughly may help improve the appropriate utilisation of MBS–subsidised health services. Further research into the reasons for the variations is needed, for example, an in-depth exploration of health providers’ attitudes about the care of older patients and patients’ experiences in receiving polypill treatments and primary care services and reimbursement of care plans. This may provide important insights on how to inform current policy development and facilitate the improvement of implementation of treatment options in primary care. Further, to maximise benefits of primary care, we suggest health services customised to the age-specific care needs of patients are provided and better guidelines around appropriate preventive care for older people are developed.

5. Strengths and Limitations

The major strength of our study includes the large sample size and the automatic extraction of individual patient data which ensures reliability and integrity of data and minimises the potential sampling bias and inaccuracies of self-reported data. The large cohort of patients from 50 practices across four states increased the generalisability of the findings. However, there are also limitations. First, not all sociodemographic data (e.g., education, and the severity and duration of diseases) were available in the database. Despite controlling for several confounders, residual confounding likely persists. Second, we had no information on the indication for prescription, or reasons for not prescribing such as contraindication or medication intolerance. Therefore, age-related variation in medication treatment might be a consequence of patients’ clinical symptoms or differences in risk estimates. Third, the overall use of medications is unclear. The extracted data were written prescriptions and did not include non-prescription or over-the-counter medications. Written prescriptions do not guarantee patients took the medications. Fourth, each patient’s clinical diagnosis was extracted from electronic health records entered by primary care providers. Hence, diagnosis was not verified by source documentation. Further, diagnoses may not have been recorded correctly and so not extracted. Patients with a mental health diagnosis may receive influenza vaccination at the pharmacy and not have it recorded in their GP’s electronic health record. Fifth, health service use may be underestimated as the absence of claiming items does not reflect care support is not occurring. Sixth, this was a secondary analysis and results are based on an Australian cohort presenting to primary care, which may limit generalizability. Further, the data analysed were the baseline data of a cluster randomised controlled trial and were not collected specifically to answer the research questions. Seventh, considering the small proportion of young patients with CVD included, a comparison between young age and old age was not conducted. Future study with a large number of young people needs to be conducted to compare the item uses between young age and old age. Further, gender sub-analysis was not performed. Age variations between male and female could be the subject of future work. The limitations of this study must be considered in interpreting the results. Despite the limitations, the analysis provides a useful picture of real-world patterns of health services and medication uses in primary care practices among CVD patients. The results are not anticipated to reflect the level of quality care.
6. Conclusions

Age-related variations emerged in terms of utilisation of CDMPs, mental health care, cardiovascular medications, and influenza vaccination in participating primary care practices. GPs are appropriately targeting care plans for patients who may gain most benefit and are in most healthcare need. CVD patients < 65 years were less likely to receive CDMPs and influenza vaccination but more likely to receive mental health care MBS items than older patients. Patients < 65 years had the lowest odds of being prescribed blood-pressure-lowering medications while patients aged ≥ 85 had the lowest odds of being prescribed lipid-lowering medications and antiplatelet medications. Age-related variations found in our study may have implications for future secondary prevention strategies in primary care targeting age-specific care needs and efficient allocation of health resources. The observed differences by age offer an opportunity to optimise CVD in primary care in all age groups to address the escalating CVD burden. Ongoing efforts are warranted to ensure improved uptake and delivery of primary care services that are appropriately targeting those in most need. Further research will help deepen understandings of these variations in care.

Author Contributions: Conceptualization and Methodology, Q.T., N.H., A.K., C.H., C.K.C., T.B., R.G., C.M.R., D.L.H., N.Z., M.W., S.J., E.R.A., T.-L.L., E.H., T.U., L.B. and J.R.; Formal analysis, K.H.; Writing—original draft preparation, Q.T.; Visualization, Q.T., K.H., N.H. and J.R.; Investigation, Q.T., K.H., N.H., A.K., C.H. and J.R.; Supervision, J.R.; Project administration, Q.T. and N.H.; Funding acquisition, J.R.; Writing—review and editing, Q.T., K.H., N.H., A.K., C.H., C.K.C., T.B., R.G., C.M.R., D.L.H., N.Z., M.W., S.J., E.R.A., T.-L.L., E.H., T.U., L.B. and J.R. All authors have read and agreed to the published version of the manuscript.

Funding: This study is part of a large project (QUEL) which was funded by a National Health and Medical Research Council (NHMRC) Partnership Project Grant (APP1140807). The study received in-kind and cash support from the following partners: Amgen (cash support), Austin Health, Australian Cardiovascular Health and Rehabilitation Association, Australian Commission on Safety and Quality in Health Care, Australian Primary Health Care Nurses Association, Brisbane South PHN, Fairfield General Practice Unit, Heart Support Australia, Improvement Foundation, Inala Primary Care, National Heart Foundation of Australia, Nepean Blue Mountains PHN (cash support), Royal Australian College of General Practitioners, Sanofi (cash support), South Western Sydney PHN, The George Institute for Global Health (cash support) and University of Melbourne. J.R. is supported by a NHMRC Career Development Fellowship (APP1143538). K.H. is supported by the National Heart Foundation of Australia Postdoctoral Fellowship (102138). M.W. is supported by NHMRC grants (1080206 and 1149987). C.M.R. is supported by a NHMRC Principal Research Fellowship (APP1136372). T.L. is funded by a NHMRC Early Career Fellowship (App110230). E.R.A. was supported by a National Heart Foundation Australia postdoctoral fellowship (101884). C.K.C. is funded by a Career Development Fellowship level 2 co-funded by the NHMRC and National Heart Foundation Future Leader Award (APP1105447).

Institutional Review Board Statement: The study was conducted in accordance with the Declaration of Helsinki, and approved by the New South Wales Population & Health Services Research Ethics Committee (code: HREC/18/CIPHS/44 and date: 1 November 2018).

Informed Consent Statement: Ethics approval was granted with a waiver of consent. Patient consent was waived. It was impractical to collect individual consent from each patient because the intervention occurred at practice level, and it was not anticipated there will be any harm to individual patients.

Data Availability Statement: The data presented in this study are available on request from the corresponding author.

Acknowledgments: The study team gratefully acknowledge the continuous support of all participating Primary Health Network (PHN) and practice staff on the QUEL project. We additionally appreciate the great support of Pen CS for their assistance with data linkage and extraction for the study and other study partners for their generous contribution to the study including Inala Primary Care, Fairfield Hospital General Practice Unit, Australian Primary Health Care Nurses Association, Royal Australian College of General Practitioners, Australian Commission on Safety and Quality in
Health Care, Heart Support Australia Ltd., Austin Health, Australian Cardiovascular Health and Rehabilitation Association, National Heart Foundation, Sanofi, and Amgen. This collaborative study was supported via funding from Sanofi via the Externally Sponsored Collaboration pathway. We extend thanks to Tim Tse for his assistance with the coding of data. In addition, we thank Caroline Wu and Kane Williams for their administrative support and legal arrangements, respectively.

Conflicts of Interest: T.U. received research grants support from NHMRC and MRFF and received consulting fees from NPS MedicineWise. RG received NHMRC Solve-CHD Synergy Grant. N.Z. received grants from Australian National Health and Medical Research Council. KH received grants from NHMRC Investigator Grant (Emerging leadership). J.R. hold a fellowship from the NHMRC (GNT2007946). E.R.A. received grants from National Heart Foundation Australia-Vanguard Grant 2019. D.H. received research funds from Vifor and Lundbeck, and consulting fees from Pfizer, Amgen, Boehringer-Ingelheim, Novartis, Sanofi and Bayer. C.K.C. received NHMRC Investigator grant. C.H. received research grants from NHMRC, RACGP Foundation, HCF, Sanofi, Amgen, and Heart Research Institute. C.H. received consulting fees under sponsorship of Boehringer Ingelheim, Novo Nordisk, Pfizer, Amgen and PSA, and Gratuity payments for membership on GP Advisory Boards for Pfizer, Amgen, Astra, Zeneca, GSK and Novartis. M.W. is a consultant to Amgen, Freeline and Kyowa Kirin.

References
1. World Health Organisation. Cardiovascular Diseases. 2021. Available online: https://www.who.int/health-topics/cardiovascular-diseases/#tab=tab_1 (accessed on 24 February 2022).
2. World Health Organisation. Aging Geneva. 2021. Available online: https://www.who.int/health-topics/ageing#tab=tab_1 (accessed on 24 February 2022).
3. World Heart Federation. What is Cardiovascular Disease? 2021. Available online: https://world-heart-federation.org/what-is-cvd/ (accessed on 24 February 2022).
4. Perk, J.; De Backer, G.; Göhlke, H.; Graham, I.; Reiner, Ž.; Verschuren, M.; Albus, C.; Benlian, P.; Boysen, G.; Cifkova, R. European Guidelines on cardiovascular disease prevention in clinical practice (version 2012): The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts) Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). Eur. Heart J. 2012, 33, 1635–1701. [PubMed]
5. Woordruffe, S.; Neubeck, L.; Clark, R.A.; Gray, K.; Ferry, C.; Finan, J.; Sanderson, S.; Briffa, T.G. Australian Cardiovascular Health and Rehabilitation Association (ACRA) core components of cardiovascular disease secondary prevention and cardiac rehabilitation 2014. Heart Lung Circ. 2015, 24, 430–441. [CrossRef] [PubMed]
6. Nguyen, T.; Nguyen, H.Q.; Widiyakusuma, N.N.; Nguyen, T.H.; Pham, T.T.; Taxis, K. Enhancing prescribing of guideline-recommended medications for ischaemic heart diseases: A systematic review and meta-analysis of interventions targeted at healthcare professionals. BMJ Open 2018, 8, e018271. [CrossRef] [PubMed]
7. Australian Government Department of Health. The Australian Health System. 2021. Available online: https://www.health.gov.au/about-us/the-australian-health-system (accessed on 24 February 2022).
8. Global Access Partners. Ensuring the Sustainability of the Australian Health System. 2019. Available online: https://globalaccesspartners.org/AustraliaHealth2040_GAPTaskforceReport_Jul2019.pdf (accessed on 24 February 2022).
9. Duckett, S. Expanding the breadth of Medicare: Learning from Australia. Health Econ. Policy Law 2018, 13, 344–368.
10. Australian Government Department of Health. Chronic Disease Management—Provider Information 2016. Available online: https://www1.health.gov.au/internet/main/publishing.nsf/Content/mbsprimarycare-factsheet-chronicdisease.htm (accessed on 24 February 2022).
11. Australian Government Department of Health. GP Mental Health Treatment Medicare Items. 2012. Available online: https://www1.health.gov.au/internet/main/publishing.nsf/Content/pacd-mental-health-care-pdf-qa (accessed on 24 February 2022).
12. Koopman, C.; Vaartjes, I.; Heintjes, E.M.; Spiering, W.; van Dis, I.; Herings, R.M.; Bots, M.L. Persisting gender differences and attenuating age differences in cardiovascular drug use for prevention and treatment of coronary heart disease, 1998–2010. Eur. Heart J. 2013, 34, 3198–3205.
13. Ma, T.T.; Wong, I.C.; Man, K.K.; Chen, Y.; Crake, T.; Ozkor, M.A.; Ding, L.Q.; Wang, Z.X.; Zhang, L.; Wei, L. Effect of evidence-based therapy for secondary prevention of cardiovascular disease: Systematic review and meta-analysis. PLoS ONE 2019, 14, e0210988.
14. Hamar, G.B.; Rula, E.Y.; Wells, A.; Coberley, C.; Pope, J.E.; Larkin, S. Impact of a chronic disease management program on hospital admissions and readmissions in an Australian population with heart disease or diabetes. Popul. Health Manag. 2013, 16, 125–131. [CrossRef]
15. Fiscella, K.; Sanders, M.R. Racial and Ethnic Disparities in the Quality of Health Care. Annu. Rev. Public Health 2016, 37, 375–394. [CrossRef]
16. Hafiz, N.; Hyun, K.; Knight, A.; Hespe, C.; Chow, C.K.; Briffa, T.; Gallagher, R.; Reid, C.M.; Hare, D.L.; Zwar, N.; et al. Receipt of Government-Funded Health Services and Medication Prescriptions in the Management of Patients with Cardiovascular Disease. *Heart Lung Circ.* 2021, 30, 1516–1524. [CrossRef]

17. Ski, C.F.; King-Shier, K.M.; Thompson, D.R. Gender, socioeconomic and ethnic/racial disparities in cardiovascular disease: A time for change. *Int. J. Cardiol.* 2014, 170, 255–257. [CrossRef]

18. McPake, B.; Mahal, A. Addressing the Needs of an Aging Population in the Health System: The Australian Case. *Health Syst. Reform* 2017, 3, 236–247. [CrossRef] [PubMed]

19. Lim, M.T.; Lim, Y.M.F.; Tong, S.F.; Sivasampu, S. Age, sex and primary care setting differences in patients’ perception of community healthcare seeking behaviour towards health services. *PLoS ONE* 2019, 14, e0224260. [CrossRef] [PubMed]

20. Thompson, A.E.; Anismowicz, Y.; Miedema, B.; Hogg, W.; Wodchis, W.P.; Aubrey-Bassler, K. The influence of gender and other patient characteristics on older adults: A 2-year retrospective chart review in a primary care practice. *BMC Health Serv. Res.* 2009, 9, 217. [CrossRef]

21. Jin, H.; Tang, C.; Wei, Q.; Chen, L.; Sun, Q.; Ma, G.; Liu, N. Age-related differences in factors associated with the underuse of recommended medications in acute coronary syndrome patients at least one year after hospital discharge. *BMC Cardiovasc. Disord.* 2014, 14, 127. [CrossRef] [PubMed]

22. Kunnoor, N.S.; Devi, P.; Kamath, D.Y.; Anthony, N.; George, J. Age- and gender-related differences in drug utilisation and adverse drug reaction patterns among patients in a common care unit. *Singap. Med. J.* 2014, 55, 221–228. [CrossRef]

23. Roughhead, E.E.; Kalisch, L.M.; Ramsay, E.N.; Ryan, P.; Gilbert, A.L. Use of health services and medicines amongst Australian war veterans: A comparison of young elderly, near centenarians and centenarians. *BMJ Geriatr.* 2010, 10, 83. [CrossRef]

24. Vegda, K.; Nie, J.X.; Wang, L.; Tracy, C.S.; Moineddin, R.; Upshur, R.E. Trends in health services utilization, medication use, and health conditions among 2-year older adults: A 2-year retrospective chart review in a primary care practice. *BMC Health Serv. Res.* 2020, 21, 36. [CrossRef]

25. Pereira, M.; Araujo, C.; Dias, P.; Lunet, N.; Subirana, I.; Marrugat, J.; Capewell, S.; Bennett, K.; Azevedo, A. Age and sex inequalities in the prescription of evidence-based pharmacological therapy following an acute coronary syndrome in Portugal: The EURHOBOP study. *Eur. J. Prev. Cardiol.* 2014, 21, 1401–1408. [CrossRef] [PubMed]

26. Redfern, J.; Hafiz, N.; Hyun, K.; Knight, A.; Hespe, C.; Chow, C.K.; Briffa, T.; Gallagher, R.; Reid, C.; Hare, D.L. Quality improvement in primary care to prevent hospitalisations and improve effectiveness and efficiency of care for people living with coronary heart disease (QUEL): Protocol for a 24-month cluster randomised controlled trial in primary care. *BMC Fam. Pract.* 2014, 15, 94. [CrossRef]

27. Australian Institute of Health and Welfare. Deaths in Australia. 2021. Available online: https://www.aihw.gov.au/reports/life-expectancy-death/deaths-in-australia/contents/life-expectancy (accessed on 24 February 2022).

28. Australian Government Department of Health. MBS online-Medicare Benefits Schedule. 2021. Available online: http://www9.health.gov.au/mbs/search.cfm (accessed on 24 February 2022).

29. Caughey, G.E.; Vitry, A.I.; Ramsay, E.N.; Gilbert, A.L.; Shakib, S.; Ryan, P.; Esterman, A.; McDermott, R.A.; Roughead, E.E. Effect of a general practitioner management plan on health outcomes and hospitalisations in older patients with diabetes. *Intern. Med. J.* 2016, 46, 1430–1436. [CrossRef]

30. Payne, R.A.; Avery, A.J.; Duerden, M.; Saunders, C.L.; Simpson, C.R.; Abel, G.A. Prevalence of polypharmacy in a Scottish primary care population. *Eur. J. Clin. Pharmacol.* 2014, 70, 575–581. [CrossRef] [PubMed]

31. Bodner, E.P.; Palgi, Y.; Wyman, M.F. Ageism in Mental Health Assessment and Treatment of Older Adults. In *Contemporary Perspectives on Ageism*; Alyon, L., Tsch-Römer, C., Eds.; International Perspectives on Aging; Springer: Cham, Switzerland, 2018; pp. 241–262.

32. De Mendonça Lima, C.A.; Ivbijaro, G. Mental health and wellbeing of older people: Opportunities and challenges. *Ment. Health Fam. Med.* 2013, 10, 125–127. [PubMed]

33. Krishnamurthi, N.; Schoepfer, D.W.; Shen, H.; Whooley, M.A. Association of Mental Health Conditions with Participation in Cardiac Rehabilitation. *J. Am. Heart Assoc.* 2019, 8, e011639. [CrossRef] [PubMed]

34. Payne, R.A.; Avery, A.J.; Duerden, M.; Saunders, C.L.; Simpson, C.R.; Abel, G.A. Prevalence of polypharmacy in a Scottish primary care population. *Eur. J. Clin. Pharmacol.* 2014, 70, 575–581. [CrossRef] [PubMed]

35. Ganz, D.A.; Lamas, G.A.; Orav, E.J.; Goldman, L.; Gutierrez, P.R.; Mangione, C.M. Age-Related Differences in Management of Heart Disease: A Study of Cardiac Medication Use in an Older Cohort. *J. Am. Geriatr. Soc.* 1999, 47, 145–150. [CrossRef]

36. Azhar, G.; Hawthorne, J.; Warford, L.; Hutchison, L.; Wei, J.Y. Prescription and Over-The-Counter Medication Use in the Oldest Old in the South-Central United States. *Innov. Aging* 2017, 1 (Suppl. S1), 914. [CrossRef]

37. Sheppard, J.P.; Singh, S.; Fletcher, K.; McManus, R.J.; Mant, J. Impact of age and sex on primary preventive treatment for cardiovascular disease in the West Midlands, UK: Cross sectional study. *BMJ Br. Med. J.* 2012, 345, e4535. [CrossRef]

38. Yedlapati, S.H.; Khan, S.U.; Talluri, S.; Lone, A.N.; Khan, M.Z.; Khan, M.S.; Navar, A.M.; Gulati, M.; Johnson, H.; Baum, S.; et al. Effects of Influenza Vaccine on Mortality and Cardiovascular Outcomes in Patients with Cardiovascular Disease: A Systematic Review and Meta-Analysis. *J. Am. Heart Assoc.* 2021, 10, e019636. [CrossRef]